Engineering monoclonal antibodies to enhance drugability: A case study

This study demonstrates how DSC can be a useful tool in stability screening of engineered proteins

contributed by Malvern Panalytical | 10/29/2019

In this application note, we compare stability data predicted by DSC of different engineered antibodies with SEC-HPLC data from accelerated stability studies. For the engineered proteins studied, there is a correlation between decreased thermostabilty based on DSC data, and greater aggregation formation during accelerated stability studies.

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!

Email*

Choose a password*

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the "Small Molecule" field I want to stay up to date with the Cell and Gene field I want to stay up to date with the Bioprocessing field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.